Health & Fitness
Mon, May 14, 2012Sun, May 13, 2012Sat, May 12, 2012Fri, May 11, 2012Thu, May 10, 2012Wed, May 9, 2012Tue, May 8, 2012Mon, May 7, 2012Sat, May 5, 2012Fri, May 4, 2012Thu, May 3, 2012Wed, May 2, 2012Tue, May 1, 2012Mon, April 30, 2012Sun, April 29, 2012Sat, April 28, 2012Fri, April 27, 2012Uroplasty to Present at the 11th Annual JMP Securities Research Conference
Published in Health and Fitness on Monday, May 7th 2012 at 13:21 GMT by Market Wire
Uroplasty to Present at the 11th Annual JMP Securities Research Conference -- MINNEAPOLIS, May 7, 2012 /PRNewswire/ --
Uroplasty to Present at the 11th Annual JMP Securities Research Conference
MINNEAPOLIS, May 7, 2012 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: [ UPI ]), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, announced today that David Kaysen, President and CEO, and Medi Jiwani, Vice President and CFO, will present the Company's business strategy and financial results at the 11thAnnual JMP Securities Research Conference at 12:30 pm PT on Monday, May 14, 2012 at the Ritz-Carlton Hotel in San Francisco.
Attendance at the conference is by invitation only. A live audio webcast of the presentation will be broadcast via the Internet. Those interested in listening to the webcast may access it at [ http://wsw.com/webcast/jmp17/upi/ ], or through Uroplasty's website at [ www.uroplasty.com ]. An archived replay of the presentation will be available for 90 days.
About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only FDA-cleared neuromodulation system that delivers posterior tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder and associated symptoms of urgency, frequency and urge incontinence. We also offer Macroplastique® Implants, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at [ www.uroplasty.com ].
For Further Information: | |
Uroplasty, Inc. | EVC Group |
David Kaysen, President and CEO, or | Doug Sherk/Jenifer Kirtland (Investors), 415.568.9349 |
Medi Jiwani, Vice President, CFO, Treasurer | Chris Gale (Media), 646.201.5431 |
952.426.6140 |
SOURCE Uroplasty, Inc.
[ Back to top ] RELATED LINKS
[ http://www.uroplasty.com ]
